Skip to main content

Day: September 4, 2025

TGS and Viridien Announce Megabar Extension Phase I Multi-client Project Offshore Brazil

OSLO, Norway (4 September 2025) – TGS, a global leader in energy data and intelligence, in collaboration with joint venture partner Viridien, an advanced technology, digital and earth data company, today announced the commencement of the Megabar Extension Phase I survey in the Barreirinhas Basin offshore Northern Brazil. The 5,300 sq km multi-client 3D seismic survey will be acquired by TGS and imaged by Viridien and builds on Viridien’s Megabar survey coverage. The Barreirinhas Basin features proven petroleum systems and giant discoveries in adjacent Guyana and Suriname basins that demonstrate analogous deepwater play components. Recent licensing activity by IOCs along the equatorial margin, coupled with the success of Brazil’s 5th Cycle Permanent Concession Offer, supports growing momentum for the region. Megabar Extension Phase I...

Continue reading

Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed

Press ReleaseNicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally LicensedCompany expects to fully repay existing financial debts in 2026 NCX 470 NDA submissions in U.S. (H1 2026) and subsequently in China Milestones payable on U.S. NDA submission and on approval Glaukos extends NCX 1728 research agreement Future strategic options under consideration including collaborations or business combinations Q&A for shareholders available on the Nicox website: Q&ASeptember 4, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that it expects to be able to fully repay all existing financial debts in 2026 and provided an update on its portfolio and financial situation. This follows...

Continue reading

Sampo plc’s share buybacks 3 September 2025

Sampo plc, stock exchange release, 4 September 2025 at 8:30 am EEST Sampo plc’s share buybacks 3 September 2025                                                    On 3 September 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:                Sampo plc’s share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code)  9,176 9.55 AQEU    111,968 9.54 CEUX  28,305 9.55 TQEX  188,296 9.55 XHELTOTAL 337,745 9.55  * rounded to two decimals                      On 6 August 2025, Sampo announced a share buyback programme of up to a maximum of EUR 200 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation...

Continue reading

Viridien and TGS Announce Megabar Extension Phase I Multi-client Project Offshore Brazil

Paris, France – September 4, 2025 Viridien, an advanced technology, digital and Earth data company, in collaboration with joint venture partner TGS, a global leader in energy data and intelligence, today announced the commencement of the Megabar Extension Phase I survey in the Barreirinhas Basin offshore Northern Brazil. The 5,300 sq km multi-client 3D seismic survey will be acquired by TGS and imaged by Viridien and builds on Viridien’s existing Megabar survey coverage. The Barreirinhas Basin features proven petroleum systems and giant discoveries in adjacent Guyana and Suriname basins that demonstrate analogous deepwater plays. Recent licensing activity by IOCs along the equatorial margin, coupled with the success of Brazil’s 5th Cycle Permanent Concession Offer, supports growing momentum for the region. Megabar Extension Phase I will...

Continue reading

Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

MINNEAPOLIS and BRISBANE, Australia, Sept. 04, 2025 (GLOBE NEWSWIRE) — Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that its Special Meeting of Stockholders (the “Special Meeting”), which was originally scheduled to be held on Thursday, September 4, 2025, at 5:00 p.m. Central time (being 8:00 a.m. AEST on Friday, September 5, 2025), has been postponed. The Special Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/AVR2025SM, on Thursday, September 11, 2025, at 5:00 p.m. Central time (being 8:00 a.m. AEST on Friday, September 12, 2025). The record date for the Special Meeting,...

Continue reading

Announcement regarding the progress of the second transaction stage with strategic investor

The company previously informed that in March it attracted a strategic investor – Turkish tourism sector businessman and investor Neset Kockar, who manages international aviation, real estate, tourism and other businesses. In April, the first stage of the transaction was successfully completed, during which N. Kockar acquired 23.2% of the company’s shares from three individual shareholders. The transaction parties planned to complete the second stage of the transaction by autumn, after which N. Kockar would control 33.19% of Novaturas shares. However, the company received information that the second stage of the transaction is being terminated according to the terms of the concluded agreements, and the transaction parties will continue negotiations regarding new agreement terms. The exact date by which a new agreement may be reached...

Continue reading

Ackermans & van Haaren supports MRM Health’s Series B financing round of 55 million euros

Dear shareholder, Dear Madam, Dear Sir,Ackermans & van Haaren (AvH) supports the Series B financing round totaling 55 million euros of MRM Health, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology. For AvH, this series B financing round involves an additional investment of 3 million euros and brings its total investment in MRM Health to 10.8 million euros and its fully diluted participation to 14.1%. Please find the full press release in annex.Best regards Ackermans & van HaarenAttachmentAckermans & van Haaren supports MRM Health’s Series B financing round (20250904)

Continue reading

Spring Valley Acquisition Corp. III Announces Pricing of $200 Million Initial Public Offering

DALLAS, Sept. 04, 2025 (GLOBE NEWSWIRE) — Spring Valley Acquisition Corp. III (the “Company”), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit on September 3, 2025. The units are expected to be listed for trading on the Nasdaq Global Market under the ticker symbol “SVACU” beginning September 4, 2025. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant of the Company. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. Once the securities comprising the...

Continue reading

Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements with SurgCenter principals and existing Mesoblast shareholders, Gregory George and William Gueck (“Investors”) to issue, at its sole discretion, up to US$50.0 million (A$76.8 million)1 of unsecured convertible notes. The funding is available at Mesoblast’s option, following shareholder approval, to repay or reduce the amount owing to its secured lenders under the existing loan agreements and for general working capital purposes. Mesoblast Chief Executive Silviu Itescu said: “We appreciate the ongoing support from our major shareholders in ensuring that the Company can optimize its capital structure...

Continue reading

Acceleware Ltd. Announces Closing of Second Tranche of Non-Brokered Private Placement

CALGARY, Alberta, Sept. 03, 2025 (GLOBE NEWSWIRE) — Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), a leading innovator of cutting-edge radio frequency (“RF”) power-to-heat technologies targeting process heat for critical minerals, amine regeneration (for carbon capture and other applications), and enhanced oil production, announces that the Company closed the second tranche of the non-brokered private placement of units (the “Units”) further to press releases dated June 30, 2025, July 31, 2025, August 12, 2025 and August 29, 2025 (the “Private Placement”) and distributed a total of 2,090,000 Units under the second tranche of the Private Placement, at a price of $0.10 per Unit, for total gross proceeds of $209,000. In aggregate, the Company has received total gross proceeds of $1,000,334.20 under both the first and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.